Liberate-HR

Liberate-HR

The study is designed to evaluate the long-term efficacy and safety of LIB003 in patients with cardiovascular disease or at high risk for cardiovascular disease on stable lipid-lowering therapy who require additional LDL reduction.

Please use this link for further information:

Primary Investigator: Dean Kereiakes